

W H O T e c h n i c a l R e p o r t S e r i e s

WHO Expert Committee on Leprosy

Eighth report

*This report contains the collective views of an international group of experts and
does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health
Organization**

Contents

WHO Expert Committee on Leprosy	v
Declarations of interest	vii
1. Introduction	1
2. Leprosy in the world	3
2.1 Assessment of global data	4
2.2 Global leprosy situation in 2010	4
2.3 New case detection	4
2.4 Trends in case detection	4
2.5 Profiles of new cases	8
3. Epidemiology	11
3.1 Definition of a leprosy case	11
3.2 Classification	12
3.3 Transmission, infection and incubation period	12
3.4 Infectiousness of leprosy	13
3.5 Risk factors	13
3.6 Interaction between HIV infection and leprosy	13
3.7 Geographical variations	14
4. Chemotherapy and management	17
4.1 Chemotherapy	17
4.1.1 Standard MDT regimens	17
4.1.2 Existing second-line antileprosy drugs	18
4.1.3 Promising new antileprosy drugs	19
4.1.4 Study on the uniform multidrug therapy regimen	21
4.1.5 Combined therapy with four weeks of daily ofloxacin and rifampicin	21
4.1.6 Treatment regimens for special situations	22
4.1.7 Relapses after multidrug therapy	22
4.2 Management of leprosy reactions and neuritis	23
4.2.1 Neuritis and nerve function impairment	23
4.2.2 Leprosy reactions	23
4.2.3 Treatment of leprosy reactions	24
4.3 Disability and rehabilitation	26
4.3.1 Magnitude of the problem	26
4.3.2 Disability grading for leprosy	26
4.3.3 Prevention, limitation and management of disabilities	26
4.3.4 Self-care	27
4.3.5 Community-based rehabilitation	27
5. Social issues	29
5.1 Equity, social justice and human rights	29
5.2 Gender	29
5.3 Enhancing the involvement of affected persons	30
5.4 Stigma and stigmatization	30

5.5	Counselling	31
5.6	Residential care	31
6.	Leprosy control and prevention	33
6.1	Improving the quality of leprosy services	33
6.2	Integrating leprosy control into general health services	34
6.3	Referral system	34
6.4	Building and maintaining national capacity	36
6.5	Community awareness and education	36
6.5.1	Community awareness	36
6.5.2	Information, education and communication	37
6.6	Improving case detection	38
6.6.1	Case-finding and case-holding	38
6.6.2	Delay in diagnosis	38
6.7	Special areas and populations	38
6.7.1	Areas with a high disease burden	38
6.7.2	Areas with a low disease burden	39
6.7.3	Underserved population groups	39
6.7.4	Urban areas	40
6.8	Contact surveillance	41
6.9	Treatment adherence	42
6.9.1	Flexible treatment	42
6.10	Supply management for multidrug therapy	42
6.11	Disease prevention	43
6.11.1	Primary BCG immunization	43
6.11.2	Immunoprophylaxis of contacts	44
6.11.3	Chemoprophylaxis of contacts	44
6.11.4	Next steps – prophylaxis strategy	45
6.12	Surveillance for drug resistance	45
6.13	Monitoring and evaluation	46
6.13.1	Indicators for monitoring	46
6.13.2	Independent evaluation of leprosy programmes	48
7.	Strategy for further reducing the disease burden due to leprosy – setting targets	49
7.1	Elimination of leprosy as a public health problem	49
7.2	New targets based on case detection and disability prevention	49
8.	Research priorities	51
9.	Conclusions and recommendations	53
	Acknowledgements	55
	References	57